This is a working overview of Semax, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
== Function == Kisspeptin is involved in the regulation of endocrine function and the onset of puberty, with activation of the kisspeptin receptor triggering release of gonadotropin-releasing hormone (GnRH), and release of kisspeptin itself being inhibited by oestradiol but enhanced by GnRH. Reductions in kisspeptin levels with age may conversely be one of the reasons behind age-related declines in levels of other endocrine hormones such as luteinizing hormone.
=== Alternative medicine === In countries such as China, herbs used alone or with antithyroid medications are used to treat hyperthyroidism. Very low quality evidence suggests that traditional Chinese herbal medications may be beneficial when taken along with routine hyperthyroidism medications; however, there is no reliable evidence to determine the effectiveness of Chinese herbal medications for treating hyperthyroidism.
=== Fortification === The World Health Organization does not have any recommendations for food fortification with vitamin E. The Food Fortification Initiative does not list any countries that have mandatory or voluntary programs for vitamin E. Infant formulas have alpha-tocopherol as an ingredient. In some countries, certain brands of ready-to-eat cereals, liquid nutrition products, and other foods have alpha-tocopherol as an added ingredient.
Edward Frank Gale. For political service. Richard Gallagher. For services to the community in Aberdeen. Lucy Gannon, Writer. For services to Television Drama. Richard Ian Gardner. For services to the Police. Arthur Buchan Geddes, Sector Officer, the Coastguard Agency, Department of Transport. Arthur Samuel George, School Crossing Patrol, Portsmouth, Hampshire. For services to Road Safety. James Alexander George, Administrative Officer, Ministry of Defence. Graham James Gibb, Leader, Grampian Police and Braemar Mountain Rescue Teams. For services to Mountain Rescue. Alison Gray Gibson, Temporary Project Manager, Royal Mail, Edinburgh. For services to the Post Office. Sydney Gibson, Secretary, Fergusons Lane Tenants Association. For services to the community in Scotswood, Newcastle-upon-Tyne. Valerie Gibson. For services to the Right to Peace and Quiet Campaign. Joan Giddings, lately Office Administrator, British Apparel and Textile Confederation. For services to the Clothing Industry. Elizabeth Glasgow. For services to the community in Wester Hailes, Edinburgh. John Glover. For services to Golf. Maureen Audrey Gobbett, Higher Executive Officer, Ministry of Defence. Major Douglas George Goddard. For services to the community in Wargrave-on-Thames, Berkshire. David William Goodall. For services to Nature Conservation in Hampshire. Ian Kenmure Evans-Gordon. For political service. Stephen Goulding, Pay Band 8, the Employment Service, Department for Education and Employment. Anne Greaves. For services to the Health and Safety Commission's Occupational Health Advisory Committee.
Sources: en.wikipedia.org
=== Intergenic ORFs as elementary structural modules === Analysis of the fold potential diversity shows that the majority of the amino acid sequences encoded by the intergenic ORFs of S. cerevisiae are predicted to be foldable. More importantly, these amino acid sequences with folding potential can serve as elementary building blocks for de novo genes or integrate into pre-existing genes.
The RCMP Security Service (French: Service de sécurité de la GRC) was a branch of the Royal Canadian Mounted Police (RCMP) that had responsibility for domestic intelligence and security in Canada. It was replaced by the Canadian Security Intelligence Service (CSIS) in 1984 on the recommendation of the McDonald Commission, which was called in the wake of major scandals during the 1970s.
Although the label cited worry about blowback from United States President Donald Trump due to the lyrics, Pusha T publicly claimed it was over his and Lamar's public feuds with rapper Drake, who filed a lawsuit against Universal in 2025 for its publication of Lamar's diss "Not Like Us". Refusing to censor the verse, Clipse paid a seven-figure sum to be dropped from the deal, signing a distribution deal with Roc Nation instead but giving Def Jam a percentage of the profits from the album. The album's lyrical content and promotional press received media attention for Pusha T's outspoken criticism of his rivals Drake and Jim Jones, as well as former creative partners Kanye West and Travis Scott. Let God Sort Em Out received critical acclaim upon release, with critics praising the duo's raw, introspective lyricism and longstanding chemistry. It was preceded by one single, "Ace Trumpets", released on May 30, 2025. Although no other songs were released as standalone singles, "Chains & Whips" and "So Far Ahead" were serviced to Apple Music the evening before its release; the former would also receive a music video along with "So Be It". Clipse embarked on the Let God Sort Em Out Tour with EarthGang from August to November 2025 in additional promotion of the album.
=== Theft === Radioactive materials in RTGs are dangerous and can be used for malicious purposes. They are not useful for a genuine nuclear weapon, but still can serve in a "dirty bomb". The Soviet Union constructed many uncrewed lighthouses and navigation beacons powered by RTGs using strontium-90 (90Sr). They are very reliable and provide a steady source of power. Most have no protection, not even fences or warning signs, and the locations of some of these facilities are no longer known due to poor record keeping. In one instance, the radioactive compartments were opened by a thief. In another case, three woodsmen in Tsalenjikha Region, Georgia found two ceramic RTG orphan sources that had been stripped of their shielding; two of the woodsmen were later hospitalized with severe radiation burns after carrying the sources on their backs, and the third died. The units were eventually recovered and isolated. There are about 1,000 such RTGs in Russia, all of which have long since exceeded their designed operational lives of ten years. Most of these RTGs likely no longer function, and may need to be dismantled. Some of their metal casings have been stripped by metal hunters, despite the risk of radioactive contamination. Transforming the radioactive material into an inert form reduces the danger of theft by people unaware of the radiation hazard (such as happened in the Goiânia accident in an abandoned Cs-137 source where the caesium was present in easily water-soluble caesium chloride form).
CH2=CH2 + 3 O2 → 2 CO2 + 2 H2O, ΔH=−1327 kJ/mol (CH2CH2)O + 2.5 O2 → 2 CO2 + 2 H2O, ΔH=−1223 kJ/mol According to a kinetic analysis by Kilty and Sachtler, the following reactions describe the pathway leading to EO. In the first step, a superoxide (O2−) species is formed:
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.